STM JOURNALS

Research & Reviews: A Journal of
Pharmacology

https://journals.stmjournals.com/rrjop

ISSN: 2230-9861 (Online)
ISSN: 2349-1299 (Print)
Volume 15, Issue 3, 2025
September–December
DOI (Journal): 10.37591/RRJoP

Review RRJoP

AI-Powered Pharmacovigilance: Revolutionizing Adverse Drug Reaction Detection, Reporting, and Future Perspectives – A Review

Muchukota Sushma[1,*], Isbha S.[2], Varshita Pattar[3], Bharathi B.V.[2], G. Jyoteshwari[4]

Abstract

Pharmacovigilance is very important in drug safety as it monitors, identifies and prevents adverse drug reactions (ADR). Conventional pharmacovigilance systems are usually limited by underreporting and delay in signal detection as well as the inability to scale up. The pharmacovigilance sphere is undergoing a seismic shift with the arrival of AI. The use of AI-driven tools, such as machine learning and natural language processing, is transforming how ADR detection is being done by, for example, allowing real-time analysis of data, process automation for dealing with cases, and early signal detection even from large data sets (such as electronic health records, social media, and literature databases). This review discusses the state-of-the-art in AI-powered pharmacovigilance, assessing its efficiency and implementation difficulties, as well as legal aspects. In addition, it describes future perspectives (i.e., personalized pharmacovigilance and AI enabled predictive modelling for proactive risk management). Through the increased speed, precision and breadth of ADR monitoring, AI presents an unlimited potential to promote patients' safety and effective regulatory structures in the changing field of drug safety surveillance.

Keywords: Pharmacovigilance, adverse drug reactions, Artificial Intelligence, Machine Learning, drug safety

INTRODUCTION

Pharmacovigilance is the science as well as activities that aim at monitoring, evaluating, understanding, and preventing adverse drug effects to ensure safety of drugs and protect the public health. It is essential in assessing risk associated with drugs before and after gaining approval in the market since it does the collection and analysis of the adverse drug reaction (ADR) reports [1, 2]. However, the conventional pharmacovigilance systems are riddled with some challenges such as underreporting people's limited awareness, labor-intensive manual processes, and delayed safety signals. Insufficiencies, such as non-uniformity of data quality, poor standardization, low level of integration of various data-sources (e.g., electronic health records and social media), and dearth of resources, particularly in the low- and middle-income nations, compound their ineffectiveness. In addition, it is also difficult to monitor the non-allopathic medicines because of the weak regulatory organisations. Data sharing and surveillance made complicated by ethical issues and different worldwide regulatory requirements.

***Author for Correspondence**
Muchukota Sushma
E-mail: sushma.banthi@gmail.com

[1]Associate Professor, Department of Pharmacy Practice, Aditya Bangalore Institute of Pharmacy Education and Research-(ABIPER), Bangalore, Karnataka, India
[2]Students, Department of Pharmacy Practice, Aditya Bangalore Institute of Pharmacy Education and Research-(ABIPER), Bangalore, Karnataka, India
[3]Assistant Professor, Department of Pharmacy Practice, Vidya Siri College of Pharmacy, Bengaluru, Karnataka, India
[4]Student, Department of Pharmacy, Gautham College of Pharmacy, Bangalore, Karnataka, India

Received Date: May 17, 2025
Accepted Date: July 19, 2025
Published Date: July 21, 2025

Citation: Muchukota Sushma, Isbha S., Varshita Pattar, Bharathi B.V., G. Jyoteshwari. AI-Powered Pharmacovigilance: Revolutionizing Adverse Drug Reaction Detection, Reporting, and Future Perspectives – A Review. Research & Reviews: A Journal of Pharmacology. 2025; 15(3): 1–7p.

New technologies, such as Artificial Intelligence and Machine Learning, provide attractive solutions with increased efficiency and real-time monitoring, although data quality concerns, algorithm transparency, and ethics remain a concern [3].

Artificial intelligence (AI) is transforming healthcare through the improvement of capabilities in diagnostics, patient care, researching and general system efficiency. It is changing conventional healthcare models to more accessible, data oriented, and personal healthcare models. The major developments include AI-empowered virtual hospitals and telemedicine platforms that allow remote consultations and constant monitoring which boosts accessibility of the underserved communities substantially. Generative AI is being deployed in diagnostics, planning treatment, and medical research with smart healthcare systems supporting wearables, the use of machine learning, and assistive robotics to limit dependence on physical healthcare facilities. AI also enhances public health through optimizing supply chains, managing patients, and real time decision making using integrated systems for data [4]. Such innovations increase the diagnostic accuracy, patient empowerment, and clinical operation streamlining. Nevertheless, there are challenges, such as unequal access to the advanced AIs, moral issues, namely, data privacy and bias, and lack of adopting the AIs at the part of the healthcare providers. It is important to overcome these problems if AI is to achieve its full capability of transforming global healthcare.

Objectives and Scope of the Review

- This review will try and discuss in detail the contribution of artificial intelligence (AI) in the pharmaceutical and healthcare sector; specifically, the pharmacovigilance sector.
- It is aimed at assessing the new innovations, applications, and developments in AI at different stages of the pharmaceutical process such as the drug discovery, clinical trials, regulatory processes, and post-market surveillance.
- The review addresses the advantages and difficulties of AI adoption within the field of pharmacovigilance, including challenges with the accuracy of data, ethical locally, transparency of algorithms, and compliance to regulation.
- It introduces the practical strategies and best practices to overcome barriers in adopting AI among the pharmacovigilance and connected healthcare areas.
- The scope is on the application of AI during the drug lifecycle from development up to safety surveillance after it goes commercial using real-world examples and case studies.
- The larger effect of AI on decision-making in healthcare and clinical trials and individual treatment.
- Finally, the review addresses the state of current limitations that include requirement for good quality data, ethical considerations, and AI for transparent and explainable purposes, and proposed improvement routes [5].

FUNDAMENTALS OF PHARMACOVIGILANCE

Pharmacovigilance is the scientific and systematic activity of identifying, evaluating, understanding, and mitigating the adverse effects or any other drug-related problems. Its most important function is enhancing the safety of health care and the safety of the public through careful monitoring of public health. Some of the most important aims include detection and safety evaluation of medicine, managing the risks involved, and ensuring the rational use of drugs [6]. In the case of pharmacovigilance, this is done by evaluating spontaneous reports, electronic health records, prescribing patterns, and other clinical data to measure the degree of efficacy. Evaluating these reports involves establishing the cause-and-effect relationship, uncovering risks, identifying the mechanisms involved, and developing measures to avert the risk. These tasks are supported by the systems of structured reporting and by monitoring the medicine's life cycle [7].

The WHO, ICH, FDA, and CDSCO international organizations formulate the main pillars of global pharmacovigilance concerning the safety of drugs in accordance with international standards, harmonized guidelines, and countries' surveillance systems. Unfortunately, despite this solid structure,

the existing pharmacovigilance practices have a lot of problems. Some of these factors include: a high rate of under-reporting of adverse drug reactions, absence of an adequate database, slow response times to safety signals, and limited resources, especially in low resource settings. Regulatory complexity due to different country requirements further increases non-compliance cost for pharmaceutical companies [3–8]. Data integration and analysis from multiple sources pose technical challenges, but problems, such as conflict of interests and poor event management in clinical trials, complicate things further ethically. More practical means, such as advanced data analytics, refinement of standard procedures/templates applicable for repetitive report submissions – pharmacovigilance, require more precise and structured harmonized efforts on a global scale in order to act with responsive flexibility that meets international investment expectations to raise confidence in drug safety determination [9]. Key limitations are explained in "Table 1".

Table 1. Key limitations.

Limitation	Description
Underreporting	Many ADRs go unreported, reducing data completeness and reliability.
Data quality/consistency	Incomplete or inconsistent reports hinder causality assessment and global comparisons.
Delayed signal detection	Slow identification of rare or unexpected ADRs due to reliance on passive reporting.
Resource constraints	Insufficient personnel, technology, and funding limit system effectiveness.
Regulatory complexity	Varying global standards and requirements complicate compliance.
Data integration/analysis	Technical challenges in managing and interpreting large, diverse datasets.
Ethical/operational issues	Conflicts of interest and poor adverse event management in trials.

ARTIFICIAL INTELLIGENCE IN HEALTHCARE

The use of various types of data with NLP technology is helping AI identify Adverse Drug Reactions (ADRs) more accurately and quicker than before. AI systems are using social media, reporting systems, and electronic health records (EHRs) to extract data. Using NLP enables the automated processing of critical data involving intricate relationships among drugs, events, entity recognition, and ADR labelling which captures patient's medical histories. This method reduces the workload as well as the analysis duration, decreases the likelihood of errors, and optimizes personalized medicine through refined tailored risk assessments. Linking and analysing diverse sources of information while automating detailed work is changing pharmacovigilance into a stronger, faster, and fuller drug safety system that benefits the public [10].

AI technology improves ADR detection by surpassing the accuracy, sensitivity, and specificity achievable with traditional pharmacovigilism. Studies on machine learning and deep learning have demonstrated that they can predict ADRs with an accuracy between 76% and 90%. AI Identifies Real ADRs with greater sensitivity, some studies reporting figures as high as 90%, far exceeding the 50–60% obtained with conventional methods. Likewise, specificity, the ability to correctly identify non-ADRs, has improved to 70–75% due to AI tools. AI's development is based on its ability to analyze a range of big and varied datasets, from electronic health records and other sources, and extract meaningful knowledge from unstructured text with NLP [11]. With real-time analysis and automation, chances of mistakes and delay are minimized, leading to improved and faster detection of safety signals, which helps both pharmacovigilance and patient well-being [10–12].

AI IN ADR REPORTING AND CASE MANAGEMENT

Artificial Intelligence (AI) is completely transforming the way in which adverse drug reaction (ADR) reporting and case management is done by automating critical practices and increasing efficacy and compliance. AI-driven chatbots/virtual assistants enable smart, easy to use ADR reporting as it takes patients and HCPs step by step on interaction via prompts to get detailed and correct information. Such tools have been proven to enhance the reporting rates of patients and even lead to symptom direction. Furthermore, AI and robotic process automation (RPA) are simplifying the whole process of the Individual Case Safety Reports (ICSRs) life cycle because they are obtaining relevant information from

different sources, identifying the duplicates, allocating case priority, creating narratives, and coding events with standardized terms of medicine. This intelligent automation saves at least 40–70% of the case processing time with an increased level of accuracy, consistency, and adherence to regulations. Additionally, AI provides real time monitoring and submission tracking, enabling readiness for audits and reporting [13]. Overall, such improvements are transforming the process of pharmacovigilance allowing faster more reliable ADR case handling and encouraging more active patient involvement.

AI is considerably improving adverse drug reaction (ADR) reporting and case management in that it works smoothly with both electronic health records (EHRs) and pharmacovigilance (PV) systems and automates such sophisticated tasks as causality assessment as well as severity classification. Instead of performing their functions in silos, AI tools can directly connect with EHRs to pick and analyze unstructured and structured patient data in real-time to detect and report ADRs with no use of manual input and errors on account of automated case population. These platforms also gather information from different sources, such as clinical records, patient feedback, social media, and clinical trial data, and integrate these under a common database to aid faster signal detection and regulations compliance [13, 14]. An AI model now helps to establish if a drug is to blame for an adverse event based on clinical context, demographics and drug history and can be combined with the traditional assessment approaches for more consistent results, but expert intervention is necessary. In addition, AI can also categorize ADR severity based on lab results and narrative details which can help with sorting out of important cases for intervention. On the whole, this technology increases efficiency, accuracy, and scalability in pharmacovigilance, with a timely identification of safety threats, and an upgrading of patient care [15].

DATA SOURCES FOR AI-DRIVEN PHARMACOVIGILANCE

Electronic Health Records (EHRs)

With the aid of different data sources, AI-based pharmacovigilance enhances drug safety monitoring, simplifies the identification of adverse events, and ensures timely detection of safety signals. Electronic health records (EHRs) provide detailed information regarding a patient's tests, treatments, and medications. AI tools can sort through all types of data in EHRs to find adverse effects and confirm if there are safety concerns [11–16]. Teaming AI with EHRs makes it possible for continuous monitoring and helps automate tasks in pharmacovigilance, which increases efficiency and responsiveness.

Social Media and Patient Forums

People often report their drug experiences and results on Twitter, Facebook, and patient forums. These platforms are analysed with help from AI and NLP to find any mentions of adverse drug reactions, helping to quickly identify safety concerns. Even if this data can help pharmacovigilance, challenges, such as accurate information, proper verification, and regulatory acceptance, remain problematic [11].

Scientific Literature and Clinical Trial Databases

New ADRs and drug safety profiles are best identified by looking at published research and clinical trial findings. AI can speed up this process by automatically finding safety details in research articles and mixing them with other safety data. These databases often have reliable and well-organized data, but they do not always pick up on rare or ongoing ADRs that appear in bigger and more diverse populations [11–17].

Spontaneous Reporting Systems

Spontaneous reporting systems, such as those operated by the Food and Drug Administration (FDA) on its behalf and the World Health Organization (WHO) on its behalf, namely, the FDA's Adverse Event Reporting System (FAERS) and the WHO's VigiBase, respectively, are highly crucial to international pharmacovigilance. AI optimizes these systems, rendering automated functions, such as signals detection, elimination of duplicates, and doing trend analysis, help enhance efficiency and accuracy [11]. Although such systems are essential for maintaining compliance with regulation and

receiving timely safety signals, underreporting and the lack of constant precision of data remain a problem.

Challenges with Data Quality, Bias, and Interoperability

AI driven pharmacovigilance has various challenges such as the aspect of data quality, bias, and interoperability. Poor data can lead to erroneous signals or even missed issues as far as safety is concerned and important data needed even when AI can assist identify anomalies and standardize information. The data from sources, such as EHRs, social media, and spontaneous reports, are likely to be biased through reporting practices, patient demographics or access to healthcare, which can create a false analysis of AI. Further, coordinating data from different sources (EHRs, social media, literature, and reporting systems) through differences in formats, standards or terminologies, seamless exchange of data is of essence. In addition, adherence to data privacy regulations as well as transparency in AI models continue to be issues to address. For AI to be successful in pharmacovigilance, these challenges must be overcome for efficient and accurate monitoring of safety [11].

ETHICAL, LEGAL, AND REGULATORY CONSIDERATIONS

Though AI adoption in pharmacovigilance carries the promise of great benefits there are also vital ethical, legal, and regulatory challenges. Patient privacy must be at a priority level, and following regulations, such as GDPR and HIPAA, needs to be enforced via data de-identification, data storage, and data access. Transparency and interpretability of AI models are of critical importance, particularly considering the impact of the decisions on the patients' safety and regulatory outcomes. However complex models are often lacking in explainability which can further stall trust. To obtain regulatory acceptance, AI systems need to be validated to the GMLP and GxP standards with strict documentations, risk assessments and continued monitoring to ensure compliance as regulations change. In addition, the elimination of biases in training data is critical in taming unfair outcomes and promoting inclusivity as well as equity in drug safety monitoring. Good governance, human intervention and transparent provisions of accountability are needed to step in when AI decisions might present risk [18]. Overall, responsible implementation requires an integration between the capability of technology and protection through regulations and ethics.

CURRENT CHALLENGES AND LIMITATIONS

It has several considerable challenges that impede its effective integration in the pharmacovigilance (PV) [19]. Among the prime technical limitations, the absence of high-quality datasets significantly in the case of rare adverse events, caused by bulk under-reporting in the traditional PV systems, is the most critical one. This scarcity of data affects training of models and their ability to generalize in different clinical settings. Moreover, unstructured nature of various data sources (free-text reports, etc.) makes accurate information extraction complicated, and doubts about data consistency and completeness remain. AI models are often working as a "black box", which causes concerns regarding explainability and transparency, vital aspects for clinical and regulatory approval. AI integration with the legacy PV systems also brings technical and organizational barriers such as opposition to change, old infrastructure, and lack of inter-division cooperation. Moreover, compliance with the regulations is not easy, since there are yet to be established standards for validating AI in the field of PV, and the authorities require transparent and auditable solutions. Finally, there is a need to process private health data issues related to privacy and cybersecurity, which require adherence to current regulations such as GDPR & HIPAA. The collaboration among the AI developers, pharmacovigilance practitioners, and regulatory agencies is necessary for tackling such issues.

Human supervision and interpretability are extremely important for the safe and reliable use of AI in pharmacovigilance, (PV), but remain sources of difficulties that lead to resistance in the clinical and regulatory context. Oversight empowers clinicians and regulators to observe, assess, and act in AI-produced decisions, as emphasized by frameworks such as the EU AI Act, particularly in safety-critical industries such as PV. Nevertheless, it is cumbersome to set practical oversight because various clinical workflows are not uniformly defined. Similarly, interpretability or the capability of understanding and

explaining AI outputs is very critical in creating trust, especially when most of the advanced AI systems remain opaque "black boxes". This sense of non-transparency raises questions on bias, errors, and abuse. A set of tools and frameworks focusing on enhancements to explainability are being designed to tackle these risks, yet the adoption is slow [20]. Causation factors involve regulatory uncertainty, lack of clarity in accountability, and integration challenges with the existing PV infrastructure, human – AI collaboration to prevent over reliance on automation. These barriers demonstrate the technical, legal, and cultural knottiness surrounding responsible use of AI in pharmacovigilance.

FUTURE PERSPECTIVES AND RESEARCH DIRECTIONS

Deep learning and federated learning advanced AI technologies are completely transforming pharmacovigilance and transforming it off from reactive to be proactive and real time process. Deep learning model, such as DNNs and CNNs, perform better in detecting adverse drug reactions (ADRs) using large volumes of structured and unstructured data sources like EHR, biomedical literature, and social media. Explainable AI techniques can further build trust as it explains how certain features affect predictions [11–19]. At the same time, federated learning allows institutions to conduct joint training of models while not sharing sensitive patient data, keeping privacy and meeting regulations. These AI-enabled systems can provide real-time monitoring, predictive risk assessment and capability of incorporating variety of data sources to enhance the rate and accuracy of safety signal detection by a great margin. Automation of such tasks as case triaging and reporting also increases the scalability and minimizes the human error. Real-world examples of implementation, including that of FDA's Sentinel system and IBM Watson, demonstrate the importance of the new technologies in terms of simplifying pharmacovigilance practices and increasing public health results [11, 19, 20].

AI is making a major impact on global pharmacovigilance by helping key stakeholders, including regulators, pharmaceutical firms, healthcare workers, and researchers, work together and automate tasks [21]. AI systems can analyze extensive data such as Electronic Health Records and safety databases from around the world with the help of machine learning, natural language processing, and data mining. This makes it possible for safety signals to be instantly found across national borders while also encouraging the use of interoperable platforms for global data interchange. AI also enhances personalized pharmacovigilance by predicting ADRs for each individual patient with the help of their genomic, medical, and comorbidity data. In addition, it makes it easier to identify people at high risk and motivates patients to use digital ways to report problems. With each addition of new data, AI systems get better, helping ensure more precise and patient-specific drug safety surveillance [11–19]. These improvements are transforming pharmacovigilance into a field that is more involved, precise, and unified across the world, which benefits both public health and precision medicine.

CONCLUSIONS

AI is transforming pharmacovigilance as the process of adverse drug reaction detection and reporting is accelerated and improved in precision and scope, to tremendous extents. Through technologies, such as machine learning, natural language processing, AI facilitates real-time data analysis, routine process automation, as well as discovery of early safety signals from vast and heterogeneous data sources. This transformation avoids such critical weaknesses of historic systems as underreporting and late identification of a signal. Further, AI creates the path for personalized pharmacovigilance and predictive modelling, thus providing for proactive risk management individually adjusted to the patient profiles. However, gigantic it may be, the implementation of AI should be done with caution regarding the barriers of regulatory, ethical, and technological nature. Transparency, privacy of data, and human control of AI must be guaranteed for establishing trust and public health protection. Ultimately, integration of AI to pharmacovigilance presents a promising move in drug safety, if innovation is matched with robust regulatory oversight and responsibility.

REFERENCES

1. Ouoba K, Lehmann H, Zongo A, Pabst JY, Semdé R. Current status and challenges of pharmacovigilance of traditional medicines in French-Speaking West African (UEMOA) countries. Pharm Med. 2023 Jul;37(4):305–18.

2. Beninger P. Pharmacovigilance: an overview. Clin Ther. 2018 Dec 1;40(12):1991–2004.
3. Hamid AA, Rahim R, Teo SP. Pharmacovigilance and its importance for primary health care professionals. Korean J Fam Med. 2022 Sep 20;43(5):290.
4. Ghafur S, Patel M, Popescu M, Jangam S, Conroy D, Fontana G. Evidence for AI in healthcare. Eur J Public Health. 2024 Nov;34(Suppl_3):ckae144–821.
5. Ohana B, Sullivan J, Baker N. Validation and transparency in AI systems for pharmacovigilance: A case study applied to the medical literature monitoring of adverse events. arXiv. 2021 Dec 21;arXiv:2201.00692.
6. Aydin OC, Aydin S, Guney HZ. Defining the awareness and attitude of the clinicians through pharmacovigilance in Turkey. World J Clin Cases. 2023 Jul 16;11(20):4865.
7. van Hoof M, Chinchilla K, Härmark L, Matos C, Inácio P, van Hunsel F. Factors contributing to best practices for patient involvement in pharmacovigilance in Europe: A stakeholder analysis. Drug Saf. 2022 Oct;45(10):1083–98.
8. Khan MA, Hamid S, Babar ZU. Pharmacovigilance in high-income countries: Current developments and a review of literature. Pharmacy (Basel). 2023 Jan 6;11(1):10.
9. Singh A, Twomey K, Baker R. Global pharmacovigilance regulations: Call for re-harmonization. Clin Trials. 2018 Dec;15(6):631–2.
10. Kim HR, Sung M, Park JA, Jeong K, Kim HH, Lee S, et al. Analyzing adverse drug reaction using statistical and machine learning methods: A systematic review. Medicine (Baltimore). 2022 Jun 24;101(25):e29387.
11. Shamim MA, Shamim MA, Arora P, Dwivedi P. Artificial intelligence and big data for pharmacovigilance and patient safety. J Med Surg Public Health. 2024 Aug 1;3:100139.
12. Dsouza VS, Leyens L, Kurian JR, Brand A, Brand H. Artificial intelligence in pharmacovigilance: A systematic review on predicting adverse drug reactions in hospitalized patients. Res Social Adm Pharm. 2025 Feb 12.
13. Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel PM. Innovation in pharmacovigilance: Use of artificial intelligence in adverse event case processing. Clin Pharmacol Ther. 2019 Apr;105(4):954–61.
14. Sorbello A, Haque SA, Hasan R, Jermyn R, Hussein A, Vega A, et al. Artificial intelligence–enabled software prototype to inform opioid pharmacovigilance from electronic health records: Development and usability study. JMIR AI. 2023 Jul 18;2:e45000.
15. Létinier L, Jouganous J, Benkebil M, Bel-Létoile A, Goehrs C, Singier A, et al. Artificial intelligence for unstructured healthcare data: Application to coding of patient reporting of adverse drug reactions. Clin Pharmacol Ther. 2021 Aug;110(2):392–400.
16. Liang L, Hu J, Sun G, Hong N, Wu G, He Y, et al. Artificial intelligence-based pharmacovigilance in the setting of limited resources. Drug Saf. 2022 May;45(5):511–9.
17. Dimitsaki S, Natsiavas P, Jaulent MC. Applying AI to structured real-world data for pharmacovigilance purposes: Scoping review. J Med Internet Res. 2024 Dec 30;26:e57824.
18. Glaser M, Littlebury R. Governance of artificial intelligence and machine learning in pharmacovigilance: What works today and what more is needed? Ther Adv Drug Saf. 2024 Oct;15:20420986241293303.
19. Lamprecht IV. An investigation into the prospects of existing technologies to address the challenges faced in pharmacovigilance systems [dissertation]. Stellenbosch: Stellenbosch Univ.
20. Adenuga BA, Kibuule D, Bamitale KD, Rennie TW. Effective integration of pharmacovigilance systems at public health facilities in resource-limited settings: A qualitative study. Res Social Adm Pharm. 2020 Aug 1;16(8):1111–6.
21. Milić MK, Sinanović Š, Prodović T, Derdemez I. Digital systems in pharmacovigilance: Enhancing adverse drug reaction detection in endocrine disorders.

